In Reply We are grateful to Fau et al for conducting and providing further analyses on our data set,1 which reinforced our interpretation and the need for further investigation regarding long-term, intensive intravitreal anti–vascular endothelial growth factor (anti-VEGF) treatment. Specifically, the authors remarked on our finding of a potential increase in overall mortality in the subgroup with monthly injections for up to 24 months (odds ratio, 1.89 [95% CI, 1.06-3.36]), which is a key finding of our study.1 However, we have been conservative in drawing conclusions, because despite a relatively large sample size (8887 trial participants), the number of deaths was only 128 (1.44%). Unsurprisingly, a contrast comparing the 6-month follow-up subgroup and the 24-month follow-up subgroup was not significant in the frequentist meta-analysis. This result was confirmed by bayesian methods.1
Reibaldi M, Fallico M, Virgili G. Frequentist Analysis of Death Associated With Intravitreal Anti–Vascular Endothelial Growth Factor Therapy—Reply. JAMA Ophthalmol. 2020;138(5):586–587. doi:10.1001/jamaophthalmol.2020.0289
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.